Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma
Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma
复制标题
DOI：
10.1080/10428190802270902
复制
发表时间：
2008-01-01
影响因子：
2.6
通讯作者：
Devine, Steven M.
中科院分区：
文献类型：
--
作者：
Hamadani, Mehdi;Awan, Farrukh T.;Devine, Steven M.
滤泡性淋巴瘤(FL)向高级别组织学的转化发生在高达70%的FL患者中。关于接受异基因造血干细胞移植(HSCT)的转化FL患者的结果的研究很少。8例经组织学证实转化为弥漫性大B细胞淋巴瘤的FL患者在本院接受了HSCT。中位年龄56岁(44~63岁)。中位随访时间为60个月。接受异基因造血干细胞移植的患者的无进展存活率和4年总存活率分别为56%和66%。4名患者发生II-IV级急性GVHD，而4名患者有广泛的慢性GVHD。第100天和总无复发死亡率分别为12.5%和25%。异基因造血干细胞移植在转化的FL患者中似乎是可行的，并与可接受的治疗相关死亡率和低复发率相关。
The transformation of follicular lymphoma (FL) to high-grade histology occurs in up to 70% of FL patients. Studies reporting outcomes of transformed FL patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) are scant. Eight FL patients with histologically confirmed transformation to diffuse large B-cell lymphoma underwent HSCT at our institution. The median age was 56 years (range 44-63 years). Median follow-up is 60 months. Progression free survival and overall survival at 4-years for patients undergoing allogeneic HSCT is 56% and 66%, respectively. Four patients developed grade II-IV acute GVHD, whereas four patients had extensive chronic GVHD. Day 100 and overall non-relapse mortality rate was 12.5% and 25%, respectively. Allogeneic HSCT appears feasible in patients with transformed FL and is associated with acceptable treatment-related mortality and low relapse rates.